SA Asks: How could Trump's new executive order impact vaccine makers?
retained text
Search fieldHome page Seeking Alpha - Power to InvestorsAbout PremiumCreate free accountSearch for Symbols, analysts, keywordsLog in SA Asks: How could Trump's new executive order impact vaccine makers? Aug 22, 2026, 3:49 PM ETMerck & Co., Inc. (MRK) Stock, GSK StockXLV, PPH, SNY, IHE, XPHBy : Val Brickates Kennedy, SA News Editor Earlier this month, President Donald Trump announced an executive order aimed at changing the number and timing of vaccines recommended for children. We asked Seeking Alpha analysts Stephen Ayers, ALLKA Research, and Gen Alpha how the president's latest To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our feedback forum. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Search fieldEntering text into the input field will update the search result below Quick Insights Most analysts expect minimal impact due to legal obstacles, existing supply chains, and potential resistance or litigation. Merck (with its MMR/MMRV franchise) and GSK (with their MMR/MMRV products) have the most exposure in the pediatric vaccine space. Potential industry impact on sales is minimal for now, as the executive order is unlikely to be quickly implemented and may not change current product offerings.
document fetched 2026-08-23 06:30 · canonical https://seekingalpha.com/news/4636043-sa-asks-how-could-trumps-new-executive-order-impact-vaccine-makers?feed_item_type=news